Colicins and their potential in cancer treatment
Colicins and their potential in cancer treatment
复制标题
DOI：
10.1016/j.bcmd.2006.10.006
复制
发表时间：
2007-01-01
影响因子：
2.3
通讯作者：
Rodnina, Marina V.
中科院分区：
文献类型：
--
作者：
Lancaster, Lorna E.;Wintermeyer, Wolfgang;Rodnina, Marina V.
大肠杆菌素是由大肠杆菌产生并释放到环境中以减少来自其他细菌菌株的竞争的抗菌细胞毒素家族。大肠杆菌素通过多种作用杀死靶细胞，包括细胞质膜的去极化、非特异性DNA酶活性、高度特异性RNA酶活性或通过抑制胞壁蛋白合成。本文综述了大肠杆菌素作为潜在的抗肿瘤药物的一些重要发现。大肠杆菌素似乎以大肠杆菌素类型和细胞系依赖性方式抑制肿瘤细胞系的增殖，并且对肿瘤细胞的毒性比对体内正常细胞的毒性更大。这开启了使用细菌大肠杆菌素对抗癌症的潜力，并提出了关于大肠杆菌素靶向肿瘤细胞的作用机制、其作为抗肿瘤治疗剂的特异性和适用性的许多问题。(c)2006年爱思唯尔公司All rights reserved.
Colicins are a family of antibacterial cytotoxins produced by Escherichia coli and released into the environment to reduce competition from other bacterial strains. Colicins kill the target cell by a variety of effects that include depolarisation of the cytoplasmic membrane, a non-specific DNase activity, a highly specific RNase activity or by inhibition of murein synthesis. This review summarises some important findings that implicate colicins as potential anti-tumor agents. Colicins appear to inhibit proliferation of tumor cell lines in a colicin-type- and cell line-dependent fashion and are more toxic to tumor cells than to normal cells within the body. This opens a potential for using bacterial colicins in combating cancer and raises a number of questions concerning the mechanism of action of colicins in targeting tumor cells, their specificity and applicability as anti-tumor therapeutics. (c) 2006 Elsevier Inc. All rights reserved.